Purpose: The mammalian target of rapamycin is activated in Kaposi sarcoma (KS) and its inhibitor, rapamycin, has induced KS regression in transplant-associated KS. This study aimed to evaluate rapamycin's safety and toxicity in HIV-infected individuals with KS receiving antiretroviral therapy (ART), investigate rapamycin interactions with both protease inhibitor (PI)–containing and nonnucleoside reverse transcriptase inhibitor (NNRTI)–containing ART regimens, and assess clinical and biological endpoints including KS response and mammalian target of rapamycin-dependent signaling.
Methods: Seven participants, 4 on PI-based and 3 on NNRTI-based ART, had rapamycin titrated to achieve trough concentrations of 5–10 ng/mL. Patients were monitored for safety and KS response. KS biopsies were evaluated for changes in phosphoribosomal S6 protein, and phospho-Akt expression. Interleukin 6 and vascular endothelial growth factor levels, HIV and KS-associated herpesvirus viral loads, and CD4 counts were monitored.
Results: Despite pharmacokinetic interactions resulting in >200-fold differences in cumulative weekly rapamycin doses between participants on PI-containing and NNRTI-containing regimens, treatment was well tolerated. There were no significant changes in viral loads or cytokine levels; modest initial decreases in CD4 counts occurred in some patients. Three participants, all on PI-containing regimens and with higher rapamycin exposure, showed partial KS responses. Three of 4 subjects whose biopsies were studied at ≥day 50 showed decreased phosphoribosomal S6 protein staining.
Conclusions: Rapamycin seems safe in HIV-infected individuals with KS and can, in some cases, induce tumor regression and affect its molecular targets. Significant pharmacokinetic interactions require careful titration to achieve target drug trough concentrations but may be exploited to achieve therapeutic benefit.
*Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
†Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC
‡Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
§Department of Medicine, Beth Israel-Deaconess Medical Center, Boston, MA
‖Department of Medicine (Hematology), UCSD Moores Cancer Center, San Diego, CA
¶Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
#Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, PA
**Deaprtment of Pathology and Laboratory Medicine, Weill-Cornell Medical College, New York, NY. Kelong Han is currently in the Department of Clinical Pharmacology, Genentech Inc, South San Francisco, CA. Debasmita Roy is currently in the Developmental Genetics Program, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY
Correspondence to: Susan E. Krown, MD, PO Box 1051, Planetarium Station, 127 West 83rd Street, New York, NY (e-mail: email@example.com).
Supported by a cooperative agreement from the National Institutes of Health, UO1 CA121947 and RO1 CA163217.
Presented in part at the KSHV 12th International Workshop, September 13–19, 2009, Charleston, SC; and at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 16–19, 2010, Berlin, Germany.
The authors have no conflicts of interest to disclose.
Received August 23, 2012
Accepted October 21, 2012
Recognition that the phosphatidylinositol 3-phosphate kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway is dysregulated in many tumor types has led to numerous clinical trials of rapamycin (sirolimus) derivatives in various cancers and their regulatory approval in a few.1–4 Although HIV infection has long been associated with an increased risk of AIDS-defining cancers, and more recently with an increased risk of certain non–AIDS-defining cancers,5 the clinical use of rapamycin in HIV-infected individuals has focused on its immunosuppressive properties, chiefly to prevent rejection of solid organ allografts,6–8 and HIV-infected patients were not included in pivotal trials leading to approval of rapamycin analogs for non–AIDS-defining cancer indications.
Kaposi sarcoma (KS), the most commonly diagnosed AIDS-defining cancer worldwide, is one of several immunodeficiency-related neoplasms associated with infection with the Kaposi sarcoma–associated herpesvirus (KSHV).9 One mechanism by which KSHV may promote tumorigenesis is via activation of the PI3K/Akt/mTOR signaling pathway, which is dysregulated in many tumors (reviewed in10). In KSHV-associated tumors, several viral proteins can activate the PI3K/Akt/mTOR pathway in the absence of host mutations or deletions.11–14 The mTOR executes essential functions with respect to tumor cell growth and proliferation that result from Akt activation. Its potential as a target for KS therapy was suggested by the observation that KS regressed in a group of HIV-uninfected renal allograft recipients whose immunosuppressive therapy was changed from a cyclosporin A–based regimen to rapamycin, titrated to achieve trough concentrations of 6–10 ng/mL, although their allograft function was not adversely affected.15 In these patients, levels of phosphorylated Akt and p70S6 Kinase (a downstream target of the mTOR:Raptor complex, mTORC1, which phosphorylates ribosomal S6 protein, RPS6, to enhance translation) were elevated in pre-rapamycin KS biopsies compared with normal skin from the same individuals. These observations, supported by mechanistic studies showing direct inhibitory effects of rapamycin on KSHV-infected tumor cells11,13,16 and indirect immunomodulatory effects leading to enhanced recovery of T-cell responses to KSHV17 provided a rationale for evaluating rapamycin in HIV-associated KS.
Because rapamycin is a substrate for the drug-metabolizing enzyme cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein,18,19 we anticipated interactions with antiretroviral drugs (ART) that inhibit or induce these proteins. Indeed, when this study was initially developed in 2006, we knew of 2 reports in HIV-infected transplant recipients showing interactions between ART and drugs used to prevent graft rejection.6,7 However, these reports provided insufficient data on which to base firm recommendations about appropriate rapamycin doses to use together with different ART regimens. We also had concerns about administering an immunosuppressive agent to individuals infected with an immunosuppressive virus, but this was tempered by reports that rapamycin inhibits HIV infectivity and transcription in culture.20
With the foregoing in mind, the AIDS Malignancy Consortium (AMC), a National Cancer Institute–supported clinical trials group, designed a pilot study, AMC051, to evaluate rapamycin's safety and toxicity in HIV-infected individuals with KS receiving protease inhibitor (PI)–based or nonnucleoside reverse transcriptase inhibitor (NNRTI)–based antiretroviral regimens and to estimate the dose(s) of rapamycin required to achieve trough rapamycin concentrations between 5 and 10 ng/mL. These aims are consistent with the goals, articulated by Persad et al21 and endorsed by the AMC, of identifying significant interactions between new anticancer agents and drugs used to treat HIV infection and removing barriers to enrollment of HIV-infected cancer patients into clinical trials. As secondary objectives, we wished to evaluate the clinical response of KS to rapamycin and its effects on mTOR-dependent signaling, serum cytokines, HIV and KSHV viral loads, and CD4 T-lymphocyte counts.
PATIENTS AND METHODS
Eligible participants were HIV-infected men or women, ≥18 years old, with stable or progressing biopsy-proven KS, who were receiving a stable antiretroviral regimen of at least 3 drugs, 1 of which had to be a PI or an NNRTI, for ≥12 weeks. At least 5 measurable nonradiated cutaneous indicator lesions and additional skin lesions for biopsy were required. Lymph node, oral, gastrointestinal (GI), and/or lung KS, not requiring cytotoxic therapy, was permitted. Additional requirements included Karnofsky performance status >60, life expectancy ≥3 months, and ability to provide informed consent and comply with the protocol. Effective barrier contraception was required of all participants; women of childbearing potential were required to have a negative pregnancy test within 72 hours. The protocol and consent form were approved by each of the participating sites' institutional review boards in accordance with an assurance filed with and approved by the US Department of Health and Human Services.
The following laboratory parameters were required within 21 days before entry: hemoglobin ≥8.0gm/dL; neutrophils ≥1000 cells per cubic millimeter; platelets ≥75,000 cells per cubic millimeter; GFR >40 mL/min; total bilirubin ≤1.5X the upper limit of normal, with exceptions for elevated indirect bilirubin in subjects receiving indinavir or atazanavir; AST and ALT ≤2.5 times upper limit of normal; fasting triglycerides ≤400 mg/dL (4.5mmol/L) and total cholesterol ≤300 mg/dL (7.8 mmol/L); spot urine protein to creatinine ratio ≤0.5 and/or proteinuria ≤500 mg/day; and CD4 count >50 cells per microliter and plasma HIV RNA level <400 copies per milliliter.
Exclusion criteria included prior rapamycin treatment; active infection; prior or concurrent malignancy except basal cell skin cancer or cervical carcinoma in situ; treatment for infection or other serious illness within 14 days; infiltrate, cavitation, or consolidation on chest x-ray within 3 months; treatment for KS within 4 weeks or local therapy to any KS indicator lesion within 60 days; investigational treatments within 4 weeks; acute or chronic liver disease; and/or, grade III/IV cardiac disease. Nursing or pregnant women were excluded. Systemic corticosteroids and agents other than ART that would interfere with rapamycin metabolism or excretion were prohibited.
The protocol originally specified an initial rapamycin dose of 0.025 mg/kg/day using a liquid oral formulation (Rapamune, Wyeth Pharmaceuticals, Inc, Philadelphia, PA) at a concentration of 1 mg/mL, without a loading dose. We planned to treat 6 evaluable participants, 3 each on PI-containing and NNRTI-containing antiretroviral regimens. After the first study participant treated at this dose together with a ritonavir-boosted PI (PI/r) regimen showed an unacceptably high trough concentration after 7 days, we modified the starting doses based on analysis of data from the first patient and the literature as follows: participants receiving a PI/r regimen received 0.0015 mg/kg/day; those receiving a PI regimen without ritonavir received 0.003 mg/kg/day; and, those on an NNRTI regimen received 0.05 mg/kg/day. If the calculated daily dosage yielded volumes <0.3 mL, the daily value was multiplied by 2 or 3 to yield a volume of at least 0.3 mL; the corresponding doses were administered 3 times weekly or twice weekly, respectively. Dosing was subsequently adjusted based on trough blood rapamycin concentrations to achieve target concentrations between 5 and 10 ng/mL. Responding patients could be treated for up to 12, 4-week cycles. Participants with progressive KS at any time, or those without objective response after 6 cycles, were removed from study.
Routine clinical and laboratory assessments were performed at baseline, days 8, 15, and 29, and every 4 weeks thereafter. KS evaluations were performed as described previously22 at baseline; response was assessed every 4 weeks for the first 3 months, and every 8 weeks thereafter. Patients completing treatment with stable disease or objective response had their response status reassessed approximately 30 days after the last rapamycin dose. CD4+ T-lymphocyte count and HIV viral load (VL) were measured at baseline, week 4, and then every third cycle. KSHV VL and cytokines were measured at baseline and day 15 of cycle 1 and on day 1 of cycles 2, 3, 5, 7, 9, and 11. Rapamycin trough concentrations were measured on days 8, 15, 21, 29, 43, and 57 and every 4 weeks thereafter. We initially monitored trough concentrations by liquid chromatography tandem mass spectroscopy (Quest Diagnostics, San Juan Capistrano, CA). However, because results using this method were not available until ≥3 days after the specimen was obtained, we added backup rapamycin immunoassays to facilitate recognition of potentially toxic levels. Immunoassays were performed on an IMx analyzer (Abbott Laboratories, Chicago, IL) by microparticle enzyme immunoassay, with results available the same day. Once a participant's dose stabilized and liquid chromatography tandem mass spectroscopy trough values were consistently within the target range, backup immunoassays were discontinued. Rapamycin doses were adjusted when trough concentrations fell outside the target range as follows: new dose = current dose × (mid-range target trough concentration/actual trough concentration), where the midrange target is 7.5 ng/mL.
KS punch biopsies were performed at baseline and again within 14 days of achieving a trough rapamycin concentration within the target range. Specimens were fixed in 10% formalin.
KSHV Viral Load
Plasma was separated from whole blood using Ficoll-based gradient centrifugation, and 100 μL was used to obtain genomic DNA using the Abbott m2000 DNA Sample Preparation System (Abbott Laboratories) according to the manufacturer protocol. Quantitative real-time polymerase chain reaction was performed as described.23
HIV VL was measured using standard commercial assays having a lower limit of sensitivity of 50 RNA copies per milliliter.
Human interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) were measured in plasma using enzyme-linked immunosorbent assay kits from eBiosciences (San Diego, CA) and PeproTech (Rocky Hill, NJ), respectively.
Formalin-fixed paraffin-embedded tumor biopsies were cut into 7 μm sections, deparaffinized, rehydrated, and incubated in 3% hydrogen peroxide/10% methanol to block endogenous peroxidase. Samples were boiled for 20 minutes in 1 mM EDTA (pH 8.0) and blocked with 10% horse serum (Vector Laboratories, Burlingame, CA) in PBS/5% BSA/0.3% TritonX-100 (Blocking Buffer), then incubated with primary antibody diluted 1:100 in blocking buffer overnight at 4°C. The antibodies used were: phosphoribosomal S6 protein (pRPS6), phospho-Akt (Ser473), and phospho-Akt (T308) (Cell Signaling Technology, Inc., Danvers, MA). Primary antibodies were detected with VectaStain ABC kit (Vector Labs, Burlingame, CA) and NovaRed. Sections were counterstained with hematoxylin, mounted, and imaged using a LEICA DM microscope (Leica GmBH, Heidelberg, Germany) equipped with a 10/0.25 numerical aperture or a 40/0.75 numerical aperture N plan objective and Leica DPC480 camera.
KSHV latency-associated nuclear antigen (LANA) and Ki-67 stains were performed using the BOND-MAX Autostainer (Leica Microsystems, Bonnockburn, IL) using the accompanying Bond polymer define detection kit after antigen retrieval with Bond epitope retrieval solution 2 (Leica Microsystems). The antibodies used were KSHV LANA (clone LN3; Advanced Biotechnologies, Inc, Columbia, MD) and Ki-67 (MIB-1) (DakoCytomation, Carpinteria, CA).
Biopsies were analyzed by visual scanning of the entire section. Samples were scored blinded on a scale of 0–4, where 0 indicates no staining and 4 is staining equivalent to the positive control. No staining (red color) observed in the absence of primary antibody was used as a negative control. Changes in staining score and KSHV VL from baseline to posttreatment were evaluated using the Wilcoxon signed rank test.
Characteristics of the 7 enrolled participants are shown in Table 1. They uniformly showed high CD4 T-lymphocyte counts and near-normal Karnofsky performance status. The diagnosis of KS was confirmed by positive LANA staining in all baseline biopsy specimens (data not shown).
Rapamycin Dose Titration
Table 2 summarizes rapamycin doses and trough levels. All 4 participants who received PI/r-containing ART initially overshot the maximum target trough concentration of 10 ng/mL and required multiple adjustments to regulate the dose. Indeed, the first patient who was receiving a ritonavir-boosted lopinavir regimen showed a trough level of 123 ng/mL after 7 days of treatment at a rapamycin dose of 2 mg once a day. The commercial laboratory performing the drug assays assumed that the level was an error and refused to release the data to the treatment site until the assay had been repeated, delaying dosage interruption for another week, at which time the blood level had reached 172 ng/mL. After stopping rapamycin, blood levels gradually declined to acceptable levels over 3 weeks. Despite these high levels, he showed minimal (grade 1) side effects. Although 2 subjects on NNRTI-based regimens initially overshot the maximum target trough level, only single dosage adjustments were needed to achieve consistent trough levels within the target range; 1 subject on an NNRTI-based regimen required an increase in the initial dose. As shown in Table 2, the eventual stable maintenance doses for the 4 individuals on PI/r-containing ART regimens ranged from 0.1 mg twice weekly to 0.3 mg 3 times a week, whereas for participants on NNRTI-based regimens, the range was 2.3–6.7 mg once a day, a difference of >200-fold.
Treatment was generally well tolerated. All patients experienced adverse events, but most were grade 1. Two patients had serious adverse events as follows: grade 3 infection (dental abscess) without neutropenia, attributed to a pre-existing condition (root canal) in patient 1 (this event occurred several months after the rapamycin trough level had fallen to within the desired target range); and extensive grade 3 superficial vein thrombus requiring anticoagulation, considered possibly related to rapamycin, in patient 4.
Patient 5 had 2 separate grade 2 infectious episodes without neutropenia, including pneumonia responsive to oral antibiotics and dermatomal herpes zoster. Patient 6 developed symptoms of a grade 2 upper respiratory infection, without neutropenia, that resolved without treatment. Four patients (2 each on PI-based and NNRTI-based regimens) experienced triglyceride elevations, with a maximum grade of 1 (1 patient), 2 (2 patients), and 3 (1 patient).
Effects on Markers of HIV Disease
We observed no consistent changes in HIV VL. Four of 5 participants with undetectable HIV VLs at baseline showed no change during therapy, whereas 1 patient showed an isolated increase at week 40 and again had an undetectable level at week 48. One participant showed a baseline value just above the limit of assay detection (65 copies/mL) but was not subsequently tested. Another participant with an undetectable VL at screening was later discovered to have become nonadherent to antiretroviral treatment in the interval between screening and initiation of rapamycin and had an elevated HIV VL at day 1. He subsequently resumed antiretroviral therapy, and his VL remained undetectable from week 16 through week 48.
The median baseline CD4 count was 826 cells per microliter (range: 558–1062). CD4 counts remained >400 cells per microliter for the 6 study participants in whom follow-up tests were performed (Fig. 1). Five of these 6 patients showed a >10% drop in CD4 count within the first 16 weeks. Afterwards, CD4 counts increased to baseline levels or remained level.
Effects on KSHV Plasma VL
At baseline, the median KSHV VL was 214 copies per milliliter (range: 28–56,653). There were no significant changes during rapamycin treatment. The median change during treatment was −138.8 copies per milliliter (P = 0.156).
The median treatment duration was 16 weeks (range: 4–49 weeks). Three patients showed partial KS response after 3–9 weeks (Table 2). Response duration ranged from 43 to 50 weeks. None of the responding patients relapsed during study treatment or at the 30-day follow-up. The 3 patients showing partial response were all receiving PI/r regimens and were also the patients showing the highest rapamycin trough levels. Three patients showed stable disease as the best response and 1 showed KS progression after 4 weeks. Two stable patients subsequently showed KS progression at weeks 12 and 17 of study, respectively; the third patient discontinued study participation at week 14 (relocated to another state) without having shown KS progression.
Plasma Cytokine Concentrations
At baseline, the median plasma IL-6 concentration was 8.22 pg/mL (range: 3.00–23.5), and the median plasma VEGF concentration was 187 ng/mL (range: 40.4–406). No significant changes in plasma IL-6 or VEGF concentrations were observed during treatment (data not shown).
KS Biopsy Studies
Figure 2 shows immunohistochemistry for pRPS6 in KS lesions at baseline. The top right panel shows a biopsy from subject 6, in which pRPS6 was detected both in KS spindle cells and endothelial cells lining blood vessels. The other panels show the variation in pRPS6 positivity in baseline biopsies.
All patients had at least 1 biopsy repeated while receiving rapamycin. Four patients, including the 3 who received NNRTI-based regimens and 1 (subject #3) who received a PI/r-based regimen, had biopsies repeated between days 22 and 29. All 4 patients who received PI/r-based regimens had biopsies performed at day 50 or later. On-treatment biopsies were assessed for changes from baseline in pRPS6, phospho-Akt (Ser 473), and phospho-Akt (T308) staining. Although overall no significant changes were detected in staining scores, the biopsies of some individuals showed evidence for pRPS6 inhibition. Figure 3A shows a representative section stained for pRPS6 at baseline and Figure 3B a section from the same patient after 50 days on drug. In this individual, decreased pRPS6 reactivity was observed within KS tumor cells and also within overlying epithelium. As shown in Figure 3C, 3 of 4 subjects whose biopsies were studied at day 50 or later—all of whom received PI/r-based ART regimens—showed decreased pRPS6 staining compared with baseline. In all 4, the on-study staining level was absent (score 0) or minimal (score 1), suggesting that rapamycin had affected its molecular target.
We saw no significant changes in Akt phosphorylation at either T308 or Ser473 or changes in Ki-67 or LANA staining upon treatment with rapamycin (data not shown).
KS was one of the first clinical manifestations heralding the AIDS epidemic. Although KS incidence in the United States declined after peaking in the 1980s, it has recently stabilized.24,25 At the same time, improved ART has prolonged the lives of many HIV-infected individuals, resulting in increased numbers of people living with HIV and at risk for various cancers, including KS. In low-resource settings, particularly sub-Saharan Africa where rates of both HIV and KSHV infection are much higher than in the United States and antiretroviral therapy has reached only a fraction of affected individuals, KS remains common.26–29 In both high-resource and low-resource settings, improved KS therapy is needed.
Rapamycin analogs have received US Food and Drug Administration approval for treatment of renal cell carcinoma, and other tumors have been shown to be sensitive to these agents.1,3 These tumors are considered PI3K/Akt/mTOR addicted. They are characterized molecularly by high-level phosphorylation of Akt, mTOR, and the mTORC1 targets, p70S6 Kinase and RPS6. KS lesions also express phosphorylated Akt15,30 and as shown here in Figure 1, phosphorylated RPS6. Therefore, KS can be considered a PI3K/Akt/mTOR-addicted tumor.
Our findings are consistent with those in HIV-negative renal allograft recipients15 and demonstrate that rapamycin, an allosteric inhibitor of mTORC1, can induce KS regression in at least some HIV-infected individuals without inducing serious adverse effects. However, the small sample makes any statement about the efficacy of rapamycin in AIDS-associated KS premature. Treatment was, overall, well tolerated even when initial rapamycin trough levels markedly overshot the intended range. Notably, there was no increase in HIV VL, which was not unexpected given that HIV replication depends on activated T cells and active Akt signaling.20,31 We did, however, observe modest decreases in CD4 T-lymphocyte counts in some participants. Because they all had relatively high baseline CD4 T-lymphocyte counts, the decrease did not result in levels that would raise concern about susceptibility to opportunistic infections typically associated with advanced HIV disease. Although 3 patients experienced infections, they were self-limited and/or easily treatable, were not AIDS defining, and may not have been related to rapamycin administration. A CD4 count decrease of similar magnitude among patients starting at a lower baseline level could, however, be of concern.
We observed substantial interactions between rapamycin and antiretroviral drugs, most notably PI/r. Although interactions were expected based on the prior experience in HIV-infected transplant recipients,6,7 their magnitude and the speed with which elevated levels developed was not and required marked reduction of the originally planned rapamycin dose in subjects receiving ritonavir, a particularly potent inhibitor of CYP3A4.32–37 Although it was possible to suggest a starting dose in these patients, therapeutic monitoring and dose readjustments were necessary because of the large interpatient variability in rapamycin pharmacokinetics and the variable effect of ART on its pharmacokinetics. These types of interactions have implications for the management of the growing number of HIV-infected cancer patients with the many anticancer agents whose absorption and/or metabolism are regulated by CYP enzymes.
The observation that KS regression was documented only in subjects receiving PI/r-based regimens deserves comment. Given the small sample, this may have been a chance occurrence. It is possible, however, that increased and/or more sustained rapamycin exposure accounts for both the improved therapeutic effects and the more consistent decreases in pRPS6 staining in biopsies from those patients. Alternatively, or in addition, some of the “off-target” effects of PIs, which include inhibition of Akt activation (reviewed in38), may have contributed to the observed therapeutic effects. These possibilities require further study. Finally, we note that dose-related side effects for rapamycin are not well defined. Among our patients who inadvertently achieved very high rapamycin levels, it is not clear that there were resultant adverse effects. A future study with dose escalation to levels of rapamycin higher than those targeted for chronic immunosuppression in the context of organ transplantation may be warranted. This study suggests that in patients on PI/r regimens, much higher, sustained drug levels could be readily achieved.
In conclusion, the results of this study suggest that rapamycin, and potentially other “rapalogs”, can be safely administered to patients with HIV infection and cancer. Rapamycin induced both regression of HIV-associated KS and predicted effects on mTOR targets in tumor biopsies in some patients. Thus, we believe that studies in a larger group of patients and perhaps involving dose escalation are warranted.
The authors thank Dr Richard Ambinder for helpful comments.
1. Hudes G, Carducci M, Tomczak P, et al.. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281.
2. Motzer RJ, Escudier B, Oudard S, et al.. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256–4265.
3. Hess G, Herbrecht R, Romaguera J, et al.. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27:3822–3829.
4. Yao JC, Lombard-Bohas C, Baudin E, et al.. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76.
5. Shiels MS, Pfeiffer RM, Gail MH, et al.. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–762.
6. Jain AK, Venkataramanan R, Fridell JA, et al.. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002;8:838–840.
7. Kumar MS, Sierka DR, Damask AM, et al.. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67:1622–1629.
8. Frassetto LA, Browne M, Cheng A, et al.. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816–2820.
9. Chang Y, Cesarman E, Pessin MS, et al.. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865–1869.
10. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 2003;4:343–348.
11. Sodhi A, Chaisuparat R, Hu J, et al.. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006;10:133–143.
12. Tomlinson CC, Damania B. The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol. 2004;78:1918–1927.
13. Sin SH, Roy D, Wang L, et al.. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood. 2007;109:2165–2173.
14. Witzig TE, Geyer SM, Ghobrial I, et al.. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347–5356.
15. Stallone G, Schena A, Infante B, et al.. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–1323.
16. Chaisuparat R, Hu J, Jham BC, et al.. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res. 2008;68:8361–8368.
17. Barozzi P, Riva G, Vallerini D, et al.. Indirect antitumor effects of mammalian target of rapamycin inhibitors against Kaposi sarcoma in transplant patients. Transplantation. 2009;88:597–598.
18. Kuhn JG, Chang SM, Wen PY, et al.. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13:7401–7406.
19. Ware N, MacPhee IA. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation. Curr Opin Mol Ther. 2010;12:270–283.
20. Heredia A, Amoroso A, Davis C, et al.. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A. 2003;100:10411–10416.
21. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol. 2008;26:1027–1032.
22. Cianfrocca M, Cooley TP, Lee JY, et al.. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002;20:153–159.
23. Dittmer DP. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res. 2003;63:2010–2015.
24. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117:1089–1096.
25. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010;170:1337–1345.
26. Mosam A, Aboobaker J, Shaik F. Kaposi's sarcoma in sub-Saharan Africa: a current perspective. Curr Opin Infect Dis. 2010;23:119–123.
27. Nguyen HQ, Magaret AS, Kitahata MM, et al.. Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS. 2008;22:937–945.
28. WHO, UNAIDS, UNICEF. Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland:World Health Organization; 2010.
29. Krown SE, Lee JY, Dittmer DP. More on HIV-associated Kaposi's sarcoma. N Engl J Med. 2008;358:535–536; . author reply 536.
30. Roy D, Dittmer DP. Phosphatase and tensin homolog (PTEN) on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol. 2011;179:2108–2119.
31. Roy J, Paquette JS, Fortin JF, et al.. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother. 2002;46:3447–3455.
32. Ikezoe T, Hisatake Y, Takeuchi T, et al.. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004;64:7426–7431.
33. Inaba T, Fischer NE, Riddick DS, et al.. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Lett. 1997;93:215–219.
34. Knox TA, Oleson L, von Moltke LL, et al.. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr. 2008;49:358–368.
35. Oostendorp RL, Huitema A, Rosing H, et al.. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res. 2009;15:4228–4233.
36. Schmitt C, Hofmann C, Riek M, et al.. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009;29:1175–1181.
37. Jayakanthan M, Chandrasekar S, Muthukumaran J, et al.. Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. J Mol Graph Model. 2010;28:455–463.
38. Bernstein WB, Dennis PA. Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS. 2008;3:666–675.